Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs.
To quantify the risk of symptomatic hepatic injury associated with nonsteroidal antiinflammatory drugs (NSAIDs). Five population-based studies were summarized to evaluate information on more than 1,000,000 patients using NSAIDs. The risk of clinically apparent liver injury was approximately 1 case per 10,000 patient-years of NSAID use. Only sulindac, associated with a 5-10-fold higher incidence of hepatic injury, differed significantly from other NSAIDs. Patients using diclofenac showed no higher incidence of serious liver disease than did patients using other NSAIDs. Symptomatic hepatic effects attributable to most NSAIDs are extremely rare and usually mild.